Pathophysiology and treatment of the myelodysplastic syndrome with isolated 5q deletion

Haematologica

Volumn 95, Issue 3, 2010, Pages 348-351

  Jädersten, Martin ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; MICRORNA; PROTEIN RPS14; RIBOSOME PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; BONE MARROW CELL; CELL DIFFERENTIATION; CHROMOSOME 5Q; CHROMOSOME DELETION 5; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; EDITORIAL; ERYTHROID CELL; ERYTHROPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; KARYOTYPE; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NONHUMAN; PATHOPHYSIOLOGY; PROGNOSIS; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; THROMBOCYTOSIS; TREATMENT RESPONSE;

CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 5; HUMANS; MYELODYSPLASTIC SYNDROMES; THALIDOMIDE;

EID: 77949732135     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.019141     Document Type: Editorial

References (25)

1. Giagounidis AA, Germing U, Haase S, Hildebrandt B, Schlegelberger B, Schoch C, et al. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia. 2004;18(1):113-9.
2. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2008.
3. Nilsson L, Astrand-Grundstrom I, Arvidsson I, Jacobsson B, Hellstrom-Lindberg E, Hast R, et al. Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level. Blood. 2000;96(6):2012-21.
4. Jaju RJ, Jones M, Boultwood J, Kelly S, Mason DY, Wainscoat JS, et al. Combined immunophenotyping and FISH identifies the involvement of B-cells in 5q- syndrome. Genes Chromosomes Cancer. 2000; 29(3):276-80.
5. Kiladjian JJ, Bourgeois E, Lobe I, Braun T, Visentin G, Bourhis JH, et al. Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes. Leukemia. 2006;20(3):463-70.
6. Boultwood J, Fidler C, Strickson AJ, Watkins F, Gama S, Kearney L, et al. Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome. Blood. 2002;99(12):4638-41.
7. Ebert BL, Pretz J, Bosco J, Chang CY, Tamayo P, Galili N, et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature. 2008;451(7176):335-9.
8. Ebert BL. Deletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancer. Leukemia. 2009; 23(7):1252-6.
9. Starczynowski DT, Kuchenbauer F, Argiropoulos B, Sung S, Morin R, Muranyi A, et al. Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat Med. 2010;16(1):49-58.
10. Pellagatti A, Jadersten M, Forsblom AM, Cattan H, Christensson B, Emanuelsson EK, et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci USA. 2007; 104(27):11406-11.
11. Framson PE, Sage EH. SPARC and tumor growth: where the seed meets the soil? J Cell Biochem. 2004;92(4):679-90.
12. Barlow JL, Drynan LF, Hewett DR, Holmes LR, Lorenzo-Abalde S, Lane AL, et al. A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome. Nat Med. 2010; 16(1):59-66.
13. Garderet L, Kobari L, Mazurier C, De Witte C, Giarratana M-C, Pérot C, et al. Unimpaired terminal erythroid differentiation and preserved enucleation capacity in myelodysplastic 5q(del) clones: a single cell study. Haematologica. 2010;95(3):398-405.
14. Ximeri M, Galanopoulos A, Klaus M, Parcharidou A, Giannikou K, Psyllaki M, et al. on behalf of the Hellenic MDS Study Group. Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion. Haematologica. 2010;95(3):406-14.
15. Alessandrino EP, Amadori S, Barosi G, Cazzola M, Grossi A, Liberato LN, et al. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica. 2002;87(12):1286-306.
16. Bowen D, Culligan D, Jowitt S, Kelsey S, Mufti G, Oscier D, et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol. 2003;120(2):187-200.
17. NCCN Clinical Practice Guidelines in Oncology / Myelodysplastic Syndromes. 2008 [Available from: www.nccn.org]
18. The Nordic MDS Group Care Program. 2008 [Available from: www.nmds.org/ez4/index.php?/nmds/Nordic-Care-Programme]
19. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355(14):1456-65.
20. Melchert M, List A. Targeted therapies in myelodysplastic syndrome. Semin Hematol. 2008;45(1):31-8.
21. Gohring G, Giagounidis A, Busche G, Kreipe HH, Zimmermann M, Hellstrom-Lindberg E, et al. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression. Ann Hematol. 2009 Oct 24. [Epub ahead of print]
22. Jadersten M, Saft L, Pellagatti A, Gohring G, Wainscoat JS, Boultwood J, et al. Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression. Haematologica. 2009;94(12):1762-6.
23. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer. 2004;4(4):314-22.
24. Wei S, Chen X, Rocha K, Epling-Burnette PK, Djeu JY, Liu Q, et al. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci USA. 2009;106(31):12974-9.
25. Tehranchi R, Fadeel B, Schmidt-Mende J, Forsblom AM, Emanuelsson E, Jadersten M, et al. Antiapoptotic role of growth factors in the myelodysplastic syndromes: concordance between in vitro and in vivo observations. Clin Cancer Res. 2005;11(17):6291-9.